Disease Info Card

Synovial Sarcoma

Information about Synovial Sarcoma: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Synovial Sarcoma

Most recent studies have shown that Synovial Sarcoma shares some biological mechanisms with bone-neoplasms, carcinoma, ewings-sarcoma-primitive-neuroectodermal-tumor-(pnet), fibrosarcoma, histiocytoma, histiocytoma-benign-fibrous, leiomyosarcoma, liposarcoma, lung-neoplasms, malignant-fibrous-histiocytoma, malignant-neoplasms, malignant-paraganglionic-neoplasm, malignant-peripheral-nerve-sheath-tumor, neoplasm-metastasis, neoplasm-recurrence-local, neoplasms, osteosarcoma, rhabdomyosarcoma, sarcoma, soft-tissue-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Synovial Sarcoma, and have been seen in publications frequently: Angiogenesis, Cell Adhesion, Cell Cycle, Cell Death, Cell Differentiation, Cell Growth, Cell Proliferation, Chromatin Remodeling, Hypersensitivity, Interphase, Localization, Metaphase, Methylation, Mitosis, Oncogenesis, Ossification, Pathogenesis, Reverse Transcription, Secretion

Quite a number of genes have been found to play important roles in Synovial Sarcoma, such as BCL2, CD34, CD99, CTLA4, DES, EGFR, ENDOU, ETFA, EWSR1, EXOSC6, KIT, MUC1, NOD2, S100A10, SS18, SSX1, SSX2, STS, SYT1, VIM. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.